Small scale pharmas in Haridwar stop manufacturing hydroxychloroquine as price of raw material increases exponentially

Image
ANI General News
Last Updated : Apr 14 2020 | 6:55 AM IST

While the demand for hydroxychloroquine tablets keeps on rising worldwide, small pharmaceutical manufacturers in Haridwar have stopped producing the drug due to the sharp increase in the cost of raw materials, according to Anil Sharma, President of the Pharmaceutical Manufacturer Association in Haridwar.

"Many companies in Uttarakhand have the license for manufacturing hydroxychloroquine in Uttarakhand. However, the problem for us is that raw materials have become too costly. The raw materials which earlier used to cost Rs 9,000 per kilogram are now being sold at Rs 55,000-75,000. It is because the demand for raw materials is too high and the supply is low in the market, due to which the traders who have them are charging high prices," Sharma told ANI here.

"Further, the maximum selling price of the drug is controlled and it can be sold only at Rs 5.61, therefore, it is not possible for small companies in the MSME sector to manufacture it as our manufacturing price is working out to be more than the MRP," he added.

The Pharmaceutical Manufacturer Association President further said that the MSME sector is willing to manufacture the drug if the issue of raw materials is sorted out.

"Our Drug Controller has written to the Centre to ensure the availability of raw materials to our MSME sector pharma companies. If those raw materials arrive then we will definitely manufacture the drug and release it in the market," Sharma said.

Meanwhile, speaking on the issue, Uttarakhand Drug Controller Tajbar Singh said that he has requested the Drug Controller General of India to ensure the supply of raw material.

"Over 60 companies have been approved for the production of hydroxychloroquine here. But there is a shortage in the supply of raw materials. Production will begin as soon as raw material reaches. Have written to Drug Controller General of India on it," Singh said.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Apr 14 2020 | 6:45 AM IST

Next Story